Chemotherapy and radiotherapy of bladder cancer

Česká verzia

Authors: P. Šlampa; T. Kazda
Authors place of work: Klinika radiační onkologie LF MU MOÚ, Brno
Published in the journal: Urol List 2012; 10(2): 50-53

Summary

Radical cystectomy is the standard for the management of invasive bladder cancer. Curative radiotherapy and chemoradiotherapy is used rarely. Radiotherapy plays an unsubstitutable role in palliative treatment strategy of a locally advanced and metastatic diseases. Neoadjuvant and adjuvant chemotherapy is a part of standard treatment guidelines and may be combined with the irradiation. Patients with metastases are treated with palliative chemotherapy or with palliative radiotherapy if indicated. The radiation therapy is standardly delivered by using of 3D conformal or IMRT techniques.

Key words:
bladder cancer, chemoradiotherapy, chemotherapy, radiotherapy

Zdroje

1. Gunderson LL, Tepper JE. Clinical radiation oncology. Philadelphia: Elsevier Saunders 2012: 1099–1123.

2. Šlampa P et al. Radiační onkologie v praxi. Třetí aktualizované vydání. Brno: Masarykův onkologický ústav 2011: 195–200.

3. Šlampa P, Petera J et al. Radiační onkologie. Praha: Galén 2007: 315–324.

4. Hansen EK, Roach M. Handbook of Evidence-Based Radiation Oncology. New York: Springer 2010: 419–429.

5. Barret A, Dobbs J, Morris S et al. Practical Radiotherapy Planning. London: Hodder Arnold 2009: 351–358.

6. Vale CL. Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48(2): 202–205.

7. Bellmunt J, Orsola A, Wiegel T et al. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2011; 22 (Suppl 6): vi45–vi49.

8. NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines) Version 2.2012. online at www.NCCN.org.

9. Griffiths G, Hall R, Sylvester R et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastin chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171–2177.

10. Hussain SA, Stocken DD, Peake DR et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle inva-sive bladder cancer. Br J Cancer 2004; 90(11): 2106–2111.

11. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20(14): 3061–3071.

12. Shipley WU, Zietman AL, Kaufman DS et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates – the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005; 15(1): 36–41.

13. Santis DM, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II – results of EORTC study 30986. J Clin Oncol 2009; 27(33): 5634–5639.

14. Česká onkologická společnost. Zásady cytostatické léčby maligních onkologických onemocnění. Platnost 1. 2. 2012.

15. Cognetti F, Ruggeri EM, Felici A et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical czstectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 2011; 23(3): 695–700.

16. Vale CL. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48(2): 189–201.

17. Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastatic Rev 2009; 28(3–4): 355–367.

18. Stadler WM, Lerner SP, Groshen S et al. Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. J Clin Oncol 2011; 29(25): 3443–3449.

19. Duchesne GM, Bolger JJ, Griffiths GO et al. A randomised trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of Medical Research Council trial BA09. Int J Radiat Oncol Biol Phys 2000; 47(2): 379–388.